A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin

Bolatkale, Mustafa; Düger, Mustafa; Ülfer, Gözde; Can, Çağdaş; Acara, Ahmet Çağdaş; Yiğitbaşı, Türkan; Seyhan, Ekrem Cengiz; Bulut, Mehtap

doi:10.1016/j.ajem.2017.03.018

Cited by 27 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMA is a Food and Drug Administration (FDA) approved diagnostic indicator of the early stage of myocardial ischemia among patients having acute coronary syndrome (ACS), which can significantly reduce the missed diagnosis rate in patients with cardiovascular disease (Montagnana et al, 2008). In recent years, many new studies have found that the serum level of IMA can also be significantly increased in non-cardiogenic ischemic diseases (Sbarouni et al, 2006; Bolatkale et al, 2017). Furthermore, IMA has been shown to be an effective marker for the seriousness as well as prognosis of diseases like acute ischemic chest pain patients in emergency department (Consuegra-Sanchez et al, 2008), continuous ambulatory peritoneal dialysis patients (Su et al, 2013), and severe sepsis patients (Yin et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Ischemia-Modified Albumin, a Novel Predictive Marker of In-Hospital Mortality in Acute Aortic Dissection Patients

Yang

Zhou

et al. 2019

Front. Physiol.

View full text Add to dashboard Cite

BackgroundThis work explored the prognostic prediction capabilities of ischemia-modified albumin (IMA) in patients suffering from acute aortic dissection (AAD).MethodsWe conducted a retrospective analysis using electronic health records. This study included AAD patients admitted to the Second Xiangya Hospital of Central South University from January 2015 to December 2018 in ≤24 h from the onset of symptoms to hospital admission. The levels of IMA were recorded upon admittance and the final was the all-cause mortality during hospitalization.ResultsThis study enrolled 731 AAD patients. Among who, 160 passed away in the course of medication while 571 of them survived. Those who passed away exhibited higher levels of IMA (94.35 ± 26.84 vs. 69.14 ± 14.70, p < 0.001) than the survivors. Following the adjustment confounders, the fully adjusted model showed IMA to be an independent forecastor for in-hospital mortality for AAD patients (OR 1.10, 95% CI 1.08–1.13, p < 0.001). Analysis based on receiver operating characteristic (ROC) revealed that 79.35 μ/ml was the best threshold of IMA level. The area under the curve (AUC) based on this IMA level was 0.854 (95% CI 0.822–0.898) while the specificity and sensitivity to anticipate in-hospital death were 84.8 and 80.6%, respectively.ConclusionAdmission IMA was an independent forecastor for in-hospital mortality among people suffering from AAD.

show abstract

Section: Introductionmentioning

confidence: 99%

Ischemia-Modified Albumin, a Novel Predictive Marker of In-Hospital Mortality in Acute Aortic Dissection Patients

Yang

Zhou

et al. 2019

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…reported that the IMA elevation above 9 U/mL after a provocation test could detect the presence of coronary vasospasm with a sensitivity of 94% and a specificity of 99% . In addition, many studies reported increased serum IMA level in patients with other extracardiac diseases, such as diabetes mellitus, inflammatory bowel disease, community‐acquired pneumonia, and acute ischaemic stroke . Furthermore, two previous studies confirmed an increase in serum IMA level in AD and a significant relationship between serum IMA level and oxidative stress …”

Section: Discussionmentioning

confidence: 93%

Serum ischaemia‐modified albumin might be a potential biomarker for oxidative stress in amnestic mild cognitive impairment

et al. 2018

Psychogeriatrics

View full text Add to dashboard Cite

Background: Amnestic mild cognitive impairment (aMCI) is considered to be a prodromal stage of Alzheimer's disease. The clinical role of ischaemiamodified albumin (IMA) and the association between IMA and oxidative stress in aMCI have not been investigated. The aim of the study was to explore this relationship and to generate new ideas for controlling Alzheimer's disease. Methods: This community-based case-control study included 113 patients with aMCI and 832 cognitively normal controls. Serum levels of albumin and IMA, diacron-reactive oxygen metabolite, and biological anti-oxidant potential, were measured. The IMA/albumin ratio and the biological antioxidant potential/diacron-reactive oxygen metabolite ratio were calculated. Results: In univariate analysis, the serum IMA level and the IMA/albumin ratio were higher in the aMCI patients than in the controls (P < 0.001, P < 0.001, respectively). In multivariate analysis, a serum IMA level ≥476.4 ng/mL and an IMA/albumin ratio ≥9.4 were separately associated with the development of aMCI (odds ratio = 3.56, 95% confidence interval: 2.33-5.46; odds ratio = 3.43, 95% confidence interval: 2.25-5.27, respectively). There was a linear correlation between serum IMA level and several oxidative stress markers (biological anti-oxidant potential/diacron-reactive oxygen metabolite ratio: r = −0.585, P < 0.001; diacron-reactive oxygen metabolite: r = 0.549, P < 0.001; biological anti-oxidant potential: r = −0.293, P < 0.001). Conclusion: Serum IMA might be a potential biomarker for oxidative stress in aMCI.

show abstract

“…As stated by Akboga et al, 2 white blood cell, neutrophil, lymphocyte, monocyte, red cell distribution width, erythrocyte sedimentation rate, and serum total bilirubin levels may increase with endothelial dysfunction. 3,4 However, these parameters were not investigated in our study. 1 Another question by Akboga et al 2 is whether there is a positive correlation between hsCRP levels and endocan and ischemia-modified albumin levels.…”

mentioning

confidence: 94%

Reply to Letter by Akboga et al Entitled “Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?”

et al. 2018

View full text Add to dashboard Cite

A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin

Cited by 27 publications

References 28 publications

Ischemia-Modified Albumin, a Novel Predictive Marker of In-Hospital Mortality in Acute Aortic Dissection Patients

Ischemia-Modified Albumin, a Novel Predictive Marker of In-Hospital Mortality in Acute Aortic Dissection Patients

Serum ischaemia‐modified albumin might be a potential biomarker for oxidative stress in amnestic mild cognitive impairment

Reply to Letter by Akboga et al Entitled “Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?”

Contact Info

Product

Resources

About